Drug Product Revenue, Net was Kyntra Bio’s largest revenue line in fiscal 2025, bringing in $5.85M of $6.45M (91%).
| SEC Schedule, 12-09, Valuation Allowances and Reserves Type | FY 2020 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Net Transfer Price | — | $68.83M | — | — | — | — | |
| Bulk Drug Product | — | $57.40M | — | — | — | — | |
| Drug Product Revenue, Net | $9.80M | $30.89M | $14.40M | $18.80M | $28.57M | $5.85M | |
| Drug Product Revenue | — | — | — | — | — | — | |
| Development Revenue | — | $2.40M | — | $6.70M | $1.40M | $600.00K | |
| Decrease (Increase) In Deferred Revenue | — | $2.34M | — | — | — | — | |
| Constrained For Future Recognition | — | $2.30M | — | — | — | — | |
| Sales Returns | — | $1.00K | — | — | — | — | |
| Discounts & Rebates | — | -$665.00K | — | — | — | — | |
| Profit Share | — | -$43.72M | — | — | — | — | |
| Total | $9.80M | $119.77M | $14.40M | $25.50M | $29.97M | $6.45M |
Kyntra Bio brought in $6.45M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 78.5% from $29.97M in fiscal 2024. Drug Product Revenue, Net was the largest at $5.85M (90.7%), ahead of Development Revenue at $600.00K (9.3%).
Compared with fiscal 2024, Development Revenue fell 57.1% to $600.00K and Drug Product Revenue, Net fell 79.5% to $5.85M.
Kyntra Bio stopped reporting Net Transfer Price ($68.83M in fiscal 2022), Bulk Drug Product ($57.40M in fiscal 2022), Decrease (Increase) In Deferred Revenue ($2.34M in fiscal 2022) and two others as separate revenue lines.
Drug Product Revenue, Net was Kyntra Bio’s largest product and service line in fiscal 2025, bringing in $5.85M of $6.44M (91%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Development & Other Revenue | $966.00K | $1.95M | $592.00K | |||||
| License Revenue | $23.10M | — | — | |||||
| Product Revenue, Net | — | — | — | |||||
| Drug Product Revenue, Net | $18.75M | $27.67M | $5.85M | |||||
| Drug Product Revenue | — | — | — | |||||
| Other Revenue - Patent Transfer | $500.00K | — | — | |||||
| Total | $43.32M | $29.62M | $6.44M |
Kyntra Bio brought in $6.44M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 78.3% from $29.62M in fiscal 2024. Drug Product Revenue, Net was the largest at $5.85M (90.8%), ahead of Development & Other Revenue at $592.00K (9.2%).
Compared with fiscal 2024, Development & Other Revenue fell 69.6% to $592.00K and Drug Product Revenue, Net fell 78.9% to $5.85M.
Kyntra Bio stopped reporting License Revenue ($23.10M in fiscal 2023) and Other Revenue - Patent Transfer ($500.00K in fiscal 2023) as separate lines.
Europe was Kyntra Bio’s largest region in fiscal 2025, bringing in $5.64M of $6.44M (88%).
| Geography | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States Rest Of World & China | — | — | — | — | — | — | |||||||||
| Europe | — | $33.82M | — | $9.55M | $6.27M | $5.64M | |||||||||
| China | — | $84.63M | — | $8.43M | $91.00K | — | |||||||||
| U.S | — | $12.52M | — | $12.96M | $26.11M | — | |||||||||
| Japan | $9.80M | $9.76M | $14.40M | $15.87M | -$2.85M | $797.00K | |||||||||
| All Other | — | — | — | — | — | — | |||||||||
| Total | $9.80M | $140.73M | $14.40M | $46.80M | $29.62M | $6.44M |
Kyntra Bio brought in $6.44M from its two regions in fiscal 2025, the year ended December 31, 2025. Kyntra Bio regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $29.62M. Europe was the largest at $5.64M (87.6%), ahead of Japan at $797.00K (12.4%).
Kyntra Bio stopped reporting U.S ($26.11M in fiscal 2024) and China ($91.00K in fiscal 2024) as separate regions.
Kyntra Bio (KYNB) reports its revenue by sec schedule, 12-09, valuation allowances and reserves type, by product and service and by geography. In fiscal 2025, Drug Product Revenue, Net was its largest revenue line, bringing in $5.85M (90.7% of the total), followed by Development Revenue at $600.00K (9.3%).
Drug Product Revenue, Net was Kyntra Bio's largest revenue line in fiscal 2025, bringing in $5.85M, or 90.7% of the $6.45M total across its two revenue lines.
Drug Product Revenue, Net was Kyntra Bio's largest product and service line in fiscal 2025, bringing in $5.85M, or 90.8% of the $6.44M total across its two product and service lines.
Europe was Kyntra Bio's largest region in fiscal 2025, bringing in $5.64M, or 87.6% of the $6.44M total across its two regions.
Every figure comes from Kyntra Bio's annual financial filings, as reported. Each line keeps the name Kyntra Bio gives it, and years follow its fiscal calendar.
Kyntra Bio's revenue by sec schedule, 12-09, valuation allowances and reserves type goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.